1. Articles from Todd Campbell

    1-4 of 4
    1. Here's How Carl Icahn's Portfolio Is Changing

      Here's How Carl Icahn's Portfolio Is Changing

      Activist investor Carl Icahn is famous for making big bets on companies, and then arm-wrestling their executives into embracing shareholder friendly behaviors. Currently, Icahn owns stakes in 19 businesses that are valued at nearly $20 billion, and while there's no guarantee he'll successfully convince all those companies to pay dividends, divest non-core assets, or sell themselves lock stock and barrel, I wouldn't bet against him...

      Read Full Article
    2. Who Could Buy Bristol-Myers Squibb?

      Who Could Buy Bristol-Myers Squibb?

      Billionaire activist investor Carl Icahn has reportedly set his sights on Bristol-Myers Squibb ( NYSE:BMY ) , a $90 billion-market-cap biopharma that's carving out an important leadership position in immuno-oncology. If past is prologue, Icahn's about to start advocating for big changes at Bristol-Myers Squibb, and those could include an outright sale. Finding a buyer, however, might not be easy...

      Read Full Article
      Mentions: Leadership
    3. Why DepoMed's Shares Are Jumping 12% Today

      Why DepoMed's Shares Are Jumping 12% Today

      Following reports that its board of directors may be willing to entertain offers, DepoMed, Inc. (NASDAQ: DEPO) shares are rallying 12% at noon EST. So what Motley Fool Founders Issue New Stock Buy Alert Starboard Value LP investor Jeffrey Smith has been lobbying for DepoMed to put itself up for sale since acquiring a nearly 10% stake earlier this year, and it seems that only a year after rejecting a $33-per-share acquisition offer from Horizon Pharma (NASDAQ: HZNP) , the board is listening. Interest in......

      Read Full Article
    1-4 of 4
  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Question of The Week, Sponsored Content
  2. Topics in the News

    1. (5 articles) Board of Directors
    2. (3 articles) MDC Partners
    3. (3 articles) NYSE
    4. (2 articles) activist investors
    5. (2 articles) Nasdaq
    6. (2 articles) Management
    7. (2 articles) COVID-19
    8. (2 articles) Corporate Governance
    9. (1 articles) Leadership
    10. (1 articles) Valeant Pharmaceuticals
    11. (1 articles) MDC Partners
    12. (1 articles) Bloomberg
    13. (1 articles) Hedge Fund
    14. (1 articles) Management
    15. (1 articles) Investors
    16. (1 articles) acquisition
    17. (1 articles) Board of Directors
    18. (1 articles) Procter & Gamble
    19. (1 articles) Google
    20. (1 articles) PepsiCo
  3. Popular Articles

  4. Picture Gallery

    Why DepoMed's Shares Are Jumping 12% Today Who Could Buy Bristol-Myers Squibb? Why Valeant Pharmaceuticals Is Down 10% Today Here's How Carl Icahn's Portfolio Is Changing Icertis Adds Three-Time CEO and Corporate Governance Expert to Board of Advisors Assurant Appoints Former T-Mobile CFO J. Braxton Carter to Its Board of Directors Former L'Oréal Executive Appointed Coty's Third CEO This Year Question of the Week -- July 2 2020 MGM Growth Properties Expands it’s Board of Directors to 7 Harpoon Therapeutics Announces Changes to Board of Directors A Coronavirus Vaccine Rooted in a Government Partnership is Fueling Financial Rewards for Company Executives The agency Has Issued Guidance for Companies to Disclose Pandemic-Related Risks and Worker Protection Programs, But Some Investors Say the Move is Insufficient.